Cell therapy development

DENALI-1: Early Solid-Tumor CAR-T Response and Trial Readiness

Review A2 Bio’s early DENALI-1 CAR-T findings in solid tumors, their limitations, and the biomarker screening and monitoring work behind interpretable evidence.

By Lampgen Clinical Research

Conceptual engineered immune cell facing a solid tumor, with the headline Solid-tumor CAR-T and a reminder that the findings are early and investigational.
Conceptual editorial illustration. It does not depict a patient, an observed scan, or a proven treatment outcome.

2 min read · estimated

Sources
Early responseSmall cohort
An individual complete response warrants further study; durability and broader benefit remain unproven

What the source reported

A2 Biotherapeutics’ November 3, 2026 update described a Day 28 complete response in one patient with heavily pretreated anal cancer after investigational A2B395. DENALI-1 had treated 11 patients at its August 21 cutoff; nine were efficacy-evaluable. There was also one partial response. No dose-limiting toxicities or graft-versus-host disease were reported in this small cohort.

DENALI-1 is an open-label Phase 1/2 study without a randomized comparator. Its donor-derived, EGFR-targeted CAR-T uses an HLA-A*02 blocker intended to protect normal cells in patients whose tumors have lost that marker. An individual response does not establish durable benefit or comparative safety.

What this means for trial teams

Lampgen’s interpretation is that this program makes the link between tumor biology and site execution especially visible. Eligibility depends on more than a cancer diagnosis. Sponsors should define who verifies the required biomarker findings, which reports support eligibility, and how discrepancies are resolved before treatment. These responsibilities should be clear in the protocol, site training and escalation plan.

Prescreening also needs a patient pathway. Teams can measure referral-to-test time, inadequate specimens, inconclusive results and the proportion of potentially eligible people who reach treatment. Recording why candidates do not progress can reveal avoidable delays. This is particularly relevant when specialized testing or travel limits participation. Screening volume alone will not show whether the pathway is workable.

For CRAs and study managers, useful readiness checks include traceable eligibility evidence, reliable specimen handoffs, scheduled response assessments and timely reconciliation of adverse-event information. Investigators and medical teams retain responsibility for diagnosis, safety assessment and treatment decisions. Operational oversight should make those decisions reviewable.

The next evidence questions are response duration, reproducibility in additional patients and longer safety observation. Follow-up after treatment discontinuation also matters when the protocol requires it: stopping treatment should not automatically end outcome collection. Teams should track the reasons for missing assessments rather than treating every missing scan as equivalent.

The potential patient impact is another avenue for investigating difficult solid tumors. That promise needs a reproducible benefit-risk profile and a feasible route from referral to treatment. Lampgen supports oncology CRA staffing and clinical-operations resourcing; the relevant capability here is experience with biomarker-dependent eligibility, complex safety timelines and sustained follow-up.

Sources

  1. A2 Bio clinical update — November 3, 2026
  2. DENALI-1 study registration — NCT06682793

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?